J&J-McNeil To Co-Promote Cephalon ADHD Treatment Modafinil
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson's McNeil Consumer & Specialty Pharma unit will add Cephalon's attention deficit/hyperactivity disorder treatment modafinil to its pediatric portfolio under a Sept. 1 co-promotion pact